CompletedPhase 1NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- City of Hope Medical Center
- Principal Investigator
- Ibrahim T Aldoss, M.DCity of Hope Medical Center
- Intervention
- Acetaminophen(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2020 – 2025
Study locations (1)
- City of Hope Medical Center, Duarte, California, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04681105 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.